Moreover, widely used prostate cancer cell lines such as LNCaP, LAPC4, DU145, and PC3 each present different combinations of androgen receptor (AR) status and p53 functionality—ranging from wild-type to mutated or null—highlighting the heterogeneity of prostate tumors [46,47]. This evidence concerns the gene TP53 and Familial prostate cancer.